OXURION (EBR:OXUR) | WebDisclosure

Basculer en Français

9807	Companies
196719	Keywords
127725	Articles
104586	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 08/07/2025 at 18:00, 5 months 28 days ago

Oxurion beëindigt RD-programma voor geografische maculaire degeneratie en focust op nieuwe CRO-activiteiten
Oxurion beendet präklinisches Forschungsprogramm zur Entwicklung neuer Therapieziele für altersbedingte Makuladegeneration (GA) und fokussiert auf CRO-Aktivitäten und Profitabilität. Integrierte Datenexpertise und externe Expansion im Fokus

Profitabilität Oxurion Präklinisches Forschungsprogramm GA CRO-Aktivitäten
PRESS RELEASE

published on 08/07/2025 at 18:00, 5 months 28 days ago

Oxurion Receives Transparency Notifications from UBS Group AG
Oxurion NV received transparency notifications from UBS Group AG regarding share holdings, in compliance with Belgian Transparency legislation. The company is a biopharmaceutical group focusing on therapeutic innovation and clinical research technologies

Clinical Research Biopharmaceutical UBS Group AG Oxurion NV Transparency Notifications
PRESS RELEASE

published on 08/07/2025 at 18:00, 5 months 28 days ago

Oxurion ontvangt transparantiekennisgevingen van UBS Group AG
Oxurion NV (Euronext Brussel: OXUR) ontvangt transparantiekennisgevingen van UBS Group AG over aandelentransacties conform Belgische wetgeving. Oxurion, biofarmaceutisch bedrijf in Leuven, België, integreert innovatie en klinisch onderzoekstechnologieën

Transparantiekennisgevingen UBS Group AG Oxurion NV Biofarmaceutisch Belgische Wetgeving
BRIEF

published on 08/06/2025 at 18:05, 5 months 29 days ago

Oxurion reçoit des notifications de transparence d'Atlas Special Opportunities II LLC

Actionnariat Transparence Biopharmaceutique Oxurion Opportunités Spéciales Atlas
BRIEF

published on 08/06/2025 at 18:05, 5 months 29 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Transparency Biopharmaceutical Shareholding Atlas Special Opportunities Oxurion
PRESS RELEASE

published on 08/06/2025 at 18:00, 5 months 29 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notifications regarding changes in shareholding from Atlas Special Opportunities II, LLC as per Belgian Transparency legislation. Company combines therapeutic innovation with technology for new treatments

Clinical Research Shareholding Changes Oxurion NV Therapeutic Innovation Transparency Notifications
PRESS RELEASE

published on 08/06/2025 at 18:00, 5 months 29 days ago

Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
Oxurion NV ontvangt transparantiekennisgevingen over aandelentransacties en stimuleert therapeutische innovatie in biofarmaceutica. Zie voor meer informatie www.oxurion.com

Aandelentransacties Transparantiekennisgevingen Oxurion NV Therapeutische Innovatie Biofarmaceutica
BRIEF

published on 08/04/2025 at 18:05, 6 months ago

Oxurion Sécurise 30 M EUR Pour Diversification en Actifs Numériques

Investissement Financement Biopharmaceutique Cryptomonnaies Oxurion
BRIEF

published on 08/04/2025 at 18:05, 6 months ago

Oxurion Secures EUR 30M for Diversification into Digital Assets

Funding Investment Cryptocurrencies Biopharmaceuticals Oxurion
PRESS RELEASE

published on 08/04/2025 at 18:00, 6 months ago

Oxurion obtient une offre de financement revue à la hausse à 30 M EUR pour lancer la diversification de sa trésorerie en actifs numériques
Oxurion NV reçoit une offre de financement de 30 millions d'euros d'Atlas Special Opportunities pour investir dans Bitcoin et Ethereum. Objectif de diversification de la trésorerie

Financement Bitcoin Ethereum Oxurion NV 30 Millions D'euros

Accesswire

Published on 02/05/2026 at 09:05, 1 hour 9 minutes ago

BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
Published on 02/05/2026 at 01:35, 8 hours 39 minutes ago

Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 00:00, 10 hours 14 minutes ago

Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Published on 02/04/2026 at 22:25, 11 hours 49 minutes ago

55 North Mining Announces Flow-Through Financing
Published on 02/04/2026 at 18:00, 16 hours 14 minutes ago

Lithium South AGSM Update

View all ACCESSWIRE

EQS Group

Published on 02/05/2026 at 10:05, 9 minutes ago

VT Markets Powers Reliable Gold Trading Amid Extreme Market Volatility
Published on 02/05/2026 at 10:05, 9 minutes ago

Signing of strategic technology supply and offtake agreement with Carester, US$20 million equity investment from the Industrial Development Corporation, and commencement of DFS for the Zandkopsdrift magnet rare earths and battery grade manganese
Published on 02/05/2026 at 09:00, 1 hour 13 minutes ago

Original-Research: Eckert & Ziegler SE (von NuWays AG): BUY
Published on 02/05/2026 at 09:00, 1 hour 13 minutes ago

Original-Research: Limes Schlosskliniken AG (von NuWays AG): BUY
Published on 02/05/2026 at 09:00, 1 hour 13 minutes ago

Original-Research: Semperit AG Holding (von NuWays AG): BUY

Les Echos

Published on 02/04/2026 at 18:04, 16 hours 10 minutes ago

Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 16 hours 10 minutes ago

Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 16 hours 29 minutes ago

Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 16 hours 29 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 02/04/2026 at 17:45, 16 hours 29 minutes ago

Janvier 2026

View all LES ECHOS COMFI WIRE